Post-Translational Control of IL-1β via the Human Papillomavirus Type 16 E6 Oncoprotein: A Novel Mechanism of Innate Immune Escape Mediated by the E3-Ubiquitin Ligase E6-AP and p53

PLoS Pathogens

Volumn 9, Issue 8, 2013, Pages

  Niebler, Martina ^a   Qian, Xu ^b   Höfler, Daniela ^a   Kogosov, Vlada ^a   Kaewprag, Jittranan ^a,c   Kaufmann, Andreas M ^b   Ly, Regina ^a   Böhmer, Gerd ^d   Zawatzky, Rainer ^a   Rösl, Frank ^a   Rincon Orozco, Bladimiro ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Mahidol University ^*  (Thailand)

^d Deutsche Klinik Bad Münder   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALPAIN; CATHEPSIN B; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LEUPEPTIN; LYSOSOME ENZYME; PROTEASOME; PROTEIN E6; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; IL1B PROTEIN, HUMAN; ONCOPROTEIN; REPRESSOR PROTEIN; TP53 PROTEIN, HUMAN; UBE3A PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

AMINO ACID SEQUENCE; ARTICLE; AUTOPHAGY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNE DYSREGULATION; IMMUNE EVASION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INNATE IMMUNITY; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UBIQUITINATION; UTERINE CERVIX CANCER; VIRUS CELL INTERACTION; VIRUS CELL TRANSFORMATION; VIRUS INFECTION; WESTERN BLOTTING; CLINICAL TRIAL; FEMALE; GENETICS; IMMUNOLOGY; MALE; METABOLISM; PROTEIN DEGRADATION; TRANSFORMED CELL LINE; TUMOR ESCAPE;

CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-1BETA; MALE; ONCOGENE PROTEINS, VIRAL; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS; REPRESSOR PROTEINS; TUMOR ESCAPE; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84883368914     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003536     Document Type: Article

References (104)

1. Gravitt PE, (2011) The known unknowns of HPV natural history. J Clin Invest 121: 4593-4599.
2. zur Hausen H, (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350.
3. Badoual C, Sandoval F, Pere H, Hans S, Gey A, et al. (2010) Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies. Head Neck 32: 946-958.
4. D'Souza G, Dempsey A, (2011) The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med 53 Suppl 1: S5-S11.
5. Karim R, Meyers C, Backendorf C, Ludigs K, Offringa R, et al. (2011) Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One 6: e17848.
6. Frazer IH, (2009) Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 384: 410-414.
7. Rozenblatt-Rosen O, Deo RC, Padi M, Adelmant G, Calderwood MA, et al. (2012) Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature 487: 491-495.
8. Gulbahce N, Yan H, Dricot A, Padi M, Byrdsong D, et al. (2012) Viral perturbations of host networks reflect disease etiology. PLoS Comput Biol 8: e1002531.
9. Moody CA, Laimins LA, (2010) Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 10: 550-560.
10. Stanley MA, (2012) Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev 25: 215-222.
11. Boccardo E, Lepique AP, Villa LL, (2010) The role of inflammation in HPV carcinogenesis. Carcinogenesis 31: 1905-1912.
12. Tindle RW, (2002) Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2: 59-65.
13. Rincon-Orozco B, Halec G, Rosenberger S, Muschik D, Nindl I, et al. (2009) Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Cancer Res 69: 8718-8725.
14. Hacke K, Rincon-Orozco B, Buchwalter G, Siehler SY, Wasylyk B, et al. (2010) Regulation of MCP-1 chemokine transcription by p53. Mol Cancer 9: 82.
15. Barnard P, McMillan NA, (1999) The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 259: 305-313.
16. Sims JE, Smith DE, (2010) The IL-1 family: regulators of immunity. Nat Rev Immunol 10: 89-102.
17. Netea MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JW, et al. (2010) IL-1beta processing in host defense: beyond the inflammasomes. PLoS Pathog 6: e1000661.
18. Dinarello CA, (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27: 519-550.
19. van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA, (2011) Inflammasome activation and IL-1beta and IL-18 processing during infection. Trends Immunol 32: 110-116.
20. Rathinam VA, Vanaja SK, Fitzgerald KA, (2012) Regulation of inflammasome signaling. Nat Immunol 13: 333-332.
21. Franchi L, Munoz-Planillo R, Nunez G, (2012) Sensing and reacting to microbes through the inflammasomes. Nat Immunol 13: 325-332.
22. Khare S, Luc N, Dorfleutner A, Stehlik C, (2010) Inflammasomes and their activation. Crit Rev Immunol 30: 463-487.
23. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, et al. (2006) Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228-232.
24. Yamasaki K, Muto J, Taylor KR, Cogen AL, Audish D, et al. (2009) NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J Biol Chem 284: 12762-12771.
25. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, et al. (2008) The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 9: 857-865.
26. Zhou R, Yazdi AS, Menu P, Tschopp J, (2011) A role for mitochondria in NLRP3 inflammasome activation. Nature 469: 221-225.
27. Gram AM, Frenkel J, Ressing ME, (2012) Inflammasomes and viruses: cellular defence versus viral offence. J Gen Virol 93: 2063-2075.
28. Zitvogel L, Kepp O, Galluzzi L, Kroemer G, (2012) Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 13: 343-351.
29. Muhr P, Renne J, Schaefer V, Werfel T, Wittmann M, (2010) Primary human keratinocytes efficiently induce IL-1-dependent IL-17 in CCR6+ T cells. Exp Dermatol 19: 1105-1107.
30. Mizutani H, Black R, Kupper TS, (1991) Human keratinocytes produce but do not process pro-interleukin-1 (IL-1) beta. Different strategies of IL-1 production and processing in monocytes and keratinocytes. J Clin Invest 87: 1066-1071.
31. Gutowska-Owsiak D, Ogg GS, (2012) The epidermis as an adjuvant. J Invest Dermatol 132: 940-948.
32. Woodworth CD, Simpson S, (1993) Comparative lymphokine secretion by cultured normal human cervical keratinocytes, papillomavirus-immortalized, and carcinoma cell lines. Am J Pathol 142: 1544-1555.
33. Majeed GS, Glew S, Bidwell J, (1999) An association between LSIL and the high secretor phenotype of IL-1beta. Gynecol Oncol 73: 359-361.
34. Hu Y, Liu Y, Liu CB, Ling ZQ, (2011) Identification of high-risk human papillomavirus (hrHPV)-associated genes in early stage cervical squamous cell carcinomas. J Int Med Res 39: 712-728.
35. Schroder K, Tschopp J, The inflammasomes. Cell 140: 821-832.
36. Strowig T, Henao-Mejia J, Elinav E, Flavell R, (2012) Inflammasomes in health and disease. Nature 481: 278-286.
37. Barlan AU, Griffin TM, McGuire KA, Wiethoff CM, (2011) Adenovirus membrane penetration activates the NLRP3 inflammasome. J Virol 85: 146-155.
38. Williams MR, Kataoka N, Sakurai Y, Powers CM, Eskin SG, et al. (2008) Gene expression of endothelial cells due to interleukin-1 beta stimulation and neutrophil transmigration. Endothelium 15: 73-165.
39. Yin L, Chino T, Horst OV, Hacker BM, Clark EA, et al. (2010) Differential and coordinated expression of defensins and cytokines by gingival epithelial cells and dendritic cells in response to oral bacteria. BMC Immunol 11: 37.
40. Hug H, Los M, Hirt W, Debatin KM, (1999) Rhodamine 110-linked amino acids and peptides as substrates to measure caspase activity upon apoptosis induction in intact cells. Biochemistry 38: 13906-13911.
41. Luksch H, Romanowski MJ, Chara O, Tungler V, Caffarena ER, et al. (2012) Naturally occurring genetic variants of human caspase-1 differ considerably in structure and the ability to activate interleukin-1beta. Hum Mutat 34: 122-31.
42. Rabinowitz JD, White E, (2010) Autophagy and metabolism. Science 330: 1344-1348.
43. Tanida I, (2011) Autophagosome formation and molecular mechanism of autophagy. Antioxid Redox Signal 14: 2201-2214.
44. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, et al. (2011) Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 12: 222-230.
45. Harris J, Hartman M, Roche C, Zeng SG, O'Shea A, et al. (2011) Autophagy controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J Biol Chem 286: 9587-9597.
46. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, et al. (2008) Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456: 264-268.
47. Shi CS, Shenderov K, Huang NN, Kabat J, Abu-Asab M, et al. (2012) Activation of autophagy by inflammatory signals limits IL-1beta production by targeting ubiquitinated inflammasomes for destruction. Nat Immunol 13: 255-263.
48. Mizushima N, Yoshimori T, Levine B, (2010) Methods in mammalian autophagy research. Cell 140: 313-326.
49. Tanida I, Waguri S, (2010) Measurement of autophagy in cells and tissues. Methods Mol Biol 648: 193-214.
50. Seglen PO, Gordon PB, (1982) 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci U S A 79: 1889-1892.
51. Eng CH, Abraham RT, (2011) The autophagy conundrum in cancer: influence of tumorigenic metabolic reprogramming. Oncogene 30: 4687-96.
52. Johansen T, Lamark T, (2011) Selective autophagy mediated by autophagic adapter proteins. Autophagy 7: 279-296.
53. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, et al. (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4: 151-175.
54. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM, (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
55. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM, (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495-505.
56. Martinez-Noel G, Galligan JT, Sowa ME, Arndt V, Overton TM, et al. (2012) Identification and proteomic analysis of distinct UBE3A/E6AP protein complexes. Mol Cell Biol 32: 3095-3106.
57. Tian X, Isamiddinova NS, Peroutka RJ, Goldenberg SJ, Mattern MR, et al. (2011) Characterization of selective ubiquitin and ubiquitin-like protease inhibitors using a fluorescence-based multiplex assay format. Assay Drug Dev Technol 9: 165-173.
58. Hjerpe R, Aillet F, Lopitz-Otsoa F, Lang V, England P, et al. (2009) Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep 10: 1250-1258.
59. Maddocks OD, Vousden KH, (2011) Metabolic regulation by p53. J Mol Med (Berl) 89: 237-245.
60. Butz K, Ristriani T, Hengstermann A, Denk C, Scheffner M, et al. (2003) siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22: 5938-5945.
61. zur Hausen H, (2001) Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. J Natl Cancer Inst 93: 252-253.
62. Sasagawa T, Takagi H, Makinoda S, (2012) Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J Infect Chemother 18: 807-15.
63. Bhat P, Mattarollo SR, Gosmann C, Frazer IH, Leggatt GR, (2011) Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunol Rev 239: 85-98.
64. Pichlmair A, Kandasamy K, Alvisi G, Mulhern O, Sacco R, et al. (2012) Viral immune modulators perturb the human molecular network by common and unique strategies. Nature 487: 486-490.
65. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, et al. (1994) Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771.
66. Korzeniewski N, Spardy N, Duensing A, Duensing S, (2011) Genomic instability and cancer: lessons learned from human papillomaviruses. Cancer Lett 305: 113-122.
67. Goodbourn S, Didcock L, Randall RE, (2000) Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 81: 2341-2364.
68. Henao-Mejia J, Elinav E, Strowig T, Flavell RA, (2012) Inflammasomes: far beyond inflammation. Nat Immunol 13: 321-324.
69. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, et al. (2001) Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol 75: 4283-4296.
70. Cogswell JP, Godlevski MM, Wisely GB, Clay WC, Leesnitzer LM, et al. (1994) NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. J Immunol 153: 712-723.
71. Weber A, Wasiliew P, Kracht M, (2010) Interleukin-1beta (IL-1beta) processing pathway. Sci Signal 3: cm2.
72. Weber A, Wasiliew P, Kracht M, (2010) Interleukin-1 (IL-1) pathway. Sci Signal 3: cm1.
73. Kleine-Lowinski K, Rheinwald JG, Fichorova RN, Anderson DJ, Basile J, et al. (2003) Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. Int J Cancer 107: 407-415.
74. Kleine-Lowinski K, Gillitzer R, Kuhne-Heid R, Rosl F, (1999) Monocyte-chemo-attractant-protein-1 (MCP-1)-gene expression in cervical intra-epithelial neoplasias and cervical carcinomas. Int J Cancer 82: 6-11.
75. Merrick DT, Winberg G, McDougall JK, (1996) Re-expression of interleukin 1 in human papillomavirus 18 immortalized keratinocytes inhibits their tumorigenicity in nude mice. Cell Growth Differ 7: 1661-1669.
76. Lu H, Shen C, Brunham RC, (2000) Chlamydia trachomatis infection of epithelial cells induces the activation of caspase-1 and release of mature IL-18. J Immunol 165: 1463-1469.
77. Abdul-Sater AA, Koo E, Hacker G, Ojcius DM, (2009) Inflammasome-dependent caspase-1 activation in cervical epithelial cells stimulates growth of the intracellular pathogen Chlamydia trachomatis. J Biol Chem 284: 26789-26796.
78. Brown HM, Knowlton AE, Grieshaber SS, (2012) Chlamydial infection induces host cytokinesis failure at abscission. Cell Microbiol 14: 1554-1567.
79. Vyleta ML, Wong J, Magun BE, (2012) Suppression of ribosomal function triggers innate immune signaling through activation of the NLRP3 inflammasome. PLoS One 7: e36044.
80. Moors MA, Mizel SB, (2000) Proteasome-mediated regulation of interleukin-1beta turnover and export in human monocytes. J Leukoc Biol 68: 131-136.
81. Ciechanover A, (2003) The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting. Biochem Soc Trans 31: 474-481.
82. Wilkinson KD, (2009) DUBs at a glance. J Cell Sci 122: 2325-2329.
83. D'Arcy P, Linder S, (2012) Proteasome deubiquitinases as novel targets for cancer therapy. Int J Biochem Cell Biol 44: 1729-1738.
84. Ramamoorthy S, Nawaz Z, (2008) E6-associated protein (E6-AP) is a dual function coactivator of steroid hormone receptors. Nucl Recept Signal 6: e006.
85. Chung SH, Franceschi S, Lambert PF, (2010) Estrogen and ERalpha: culprits in cervical cancer? Trends Endocrinol Metab 21: 504-511.
86. Chung SH, Lambert PF, (2009) Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. Proc Natl Acad Sci U S A 106: 19467-19472.
87. White EA, Howley PM, (2013) Proteomic approaches to the study of papillomavirus-host interactions. Virology 435: 57-69.
88. Shai A, Pitot HC, Lambert PF, (2010) E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice. Cancer Res 70: 5064-5073.
89. Hiller T, Poppelreuther S, Stubenrauch F, Iftner T, (2006) Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol Biomarkers Prev 15: 1262-1267.
90. Mesplede T, Gagnon D, Bergeron-Labrecque F, Azar I, Senechal H, et al. (2012) p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. J Virol 86: 94-107.
91. Lechner MS, Laimins LA, (1994) Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 68: 4262-4273.
92. Band V, Dalal S, Delmolino L, Androphy EJ, (1993) Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells. EMBO J 12: 1847-1852.
93. Brimer N, Lyons C, Vande Pol SB, (2007) Association of E6AP (UBE3A) with human papillomavirus type 11 E6 protein. Virology 358: 303-310.
94. Allison SJ, Jiang M, Milner J, (2009) Oncogenic viral protein HPV E7 up-regulates the SIRT1 longevity protein in human cervical cancer cells. Aging (Albany NY) 1: 316-327.
95. Insinga A, Monestiroli S, Ronzoni S, Carbone R, Pearson M, et al. (2004) Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J 23: 1144-1154.
96. Hailey KL, Li S, Andersen MD, Roy M, Woods VL Jr, et al. (2009) Pro-interleukin (IL)-1beta shares a core region of stability as compared with mature IL-1beta while maintaining a distinctly different configurational landscape: a comparative hydrogen/deuterium exchange mass spectrometry study. J Biol Chem 284: 26137-26148.
97. Aguilar-Lemarroy A, Gariglio P, Whitaker NJ, Eichhorst ST, zur Hausen H, et al. (2002) Restoration of p53 expression sensitizes human papillomavirus type 16 immortalized human keratinocytes to CD95-mediated apoptosis. Oncogene 21: 165-175.
98. Mathias P, Wickham T, Moore M, Nemerow G, (1994) Multiple adenovirus serotypes use alpha v integrins for infection. J Virol 68: 6811-6814.
99. Muschik D, Braspenning-Wesch I, Stockfleth E, Rosl F, Hofmann TG, et al. (2011) Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2. PLoS One 6: e27655.
100. Schmitt M, Dondog B, Waterboer T, Pawlita M, (2008) Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol 46: 1050-1059.
101. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, et al. (2006) Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 44: 504-512.
102. Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J, et al. (2012) Prevalence and viral load of 51 genital human papillomavirus types and three subtypes. Int J Cancer.
103. Dondog B, Clifford GM, Vaccarella S, Waterboer T, Unurjargal D, et al. (2008) Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. Cancer Epidemiol Biomarkers Prev 17: 1731-1738.
104. Halec G, Schmitt M, Dondog B, Sharkhuu E, Wentzensen N, et al. (2013) Biological activity of probable/possible high-risk human papillomavirus types in cervical cancer. Int J Cancer 132: 63-71.